MedTrace Logo

Rucaparib in Combination With Nivolumab in Patients With Advanced or Metastatic Biliary Tract Cancer Following Platinum Therapy

NCT03639935 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2025-06-03

Study results available
· View outcomes & findings →

Summary

Investigators hypothesize that following first-line platinum based chemotherapy, rucaparib in combination with nivolumab, will improve progression-free survival and overall survival in BTC patients.

Conditions

  • Biliary Tract Cancer

Interventions

DRUG

Rucaparib

Rucaparib 600 mg PO BID days 1-28

DRUG

Nivolumab

Nivolumab 240 mg IV days 1 and 15

Sponsors & Collaborators

  • Dana-Farber Cancer Institute

    collaborator OTHER

  • Vanderbilt University Medical Center

    collaborator OTHER

  • University of Michigan Rogel Cancer Center

    lead OTHER

Principal Investigators

  • Vaibhav Sahai, MBBS, MS · Rogel Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-03-28
Primary Completion
2023-02-07
Completion
2024-04-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03639935 on ClinicalTrials.gov